Advanced in Peripheral Neuropathy

Hartmut Bertz

Hugstetter Str. 55, 
Freiburg, BW, DE 
Advanced in Peripheral Neuropathy
Hugstetter Str. 55, 
Freiburg, BW, DE 
OverviewLocationsClinical Research

Overview

Hartmut Bertz practices in Freiburg, Germany. Bertz is rated as an Advanced expert by MediFind in the treatment of Peripheral Neuropathy. Their top areas of expertise are Graft Versus Host Disease (GvHD), Agranulocytosis, Aspergillosis, Bone Marrow Transplant, and Bone Graft.

Their clinical research consists of co-authoring 125 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 4 articles in the study of Peripheral Neuropathy.

Locations

Hugstetter Str. 55, Freiburg, BW 79106, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia With Identical GVHD Prophylaxis - A Randomized Prospective European Trial.
Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia With Identical GVHD Prophylaxis - A Randomized Prospective European Trial.
Enrollment Status: Active_not_recruiting
Publish Date: April 22, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Phase I Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With the Anti-CD33 Antibody BI 836858 in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation
A Phase I Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With the Anti-CD33 Antibody BI 836858 in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation
Enrollment Status: Completed
Publish Date: April 20, 2022
Intervention Type: Drug
Study Drugs: F16IL2, BI 836858
Study Phase: Phase 1
View 1 Less Clinical Trial

125 Total Publications

The importance of systemic inflammatory response measurements as pretransplant risk factors for outcome after allogeneic haematopoietic cell transplantation.
The importance of systemic inflammatory response measurements as pretransplant risk factors for outcome after allogeneic haematopoietic cell transplantation.
Journal: British journal of haematology
Published: February 18, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Bertz's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 7 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile